lung cancer
Cizzle Biotechnology expands US rollout of lung cancer blood test
July 27, 2026Blood test, Cizzle Biotechnology, lung cancer
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung cancer in Texas in the …
SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
May 22, 2026SMC, amivantamab, lazertinib, lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for use within NHS Scotland as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
August 21, 2025Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …
Graphene-based biosensor to support new lung cancer screening test
August 18, 2025Business Services, Research and Development Ease Healthcare, Hawkeye Bio, HydroGraph, Oncology, lung cancer
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and Ease Healthcare to support the …
FDA approves diagnostic tool for MET-targeted lung cancer therapy
May 19, 2025Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
April 4, 2025Research and Development CHMP, Oncology, bristol myers squibb, immunotherapy, lung cancer, opdivo
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for …
Imidex and Spesana collaborate over impact of AI in lung nodule and mass detection
July 12, 2024Research and Development Imidex, Oncology, Spesana, artificial intelligence, cancer detection, lung cancer
Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …
iOnctura expands clinical trial programme for NSCLC
July 9, 2024Research and Development NSCLC, Oncology, clinical trial, iOnctura, lung cancer
iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.
AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment
July 8, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …
AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment
June 25, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …
CHMP recommends AstraZeneca’s Tagrisso for approval for lung cancer treatment
June 3, 2024Medical Communications CHMP, EMA, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) alongside pemetrexed and platinum-based chemotherapy, has been recommended for approval in the EU for …
FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
May 17, 2024Medical Communications Amgen, FDA, Oncology, lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) for the treatment of adult …
J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer
April 29, 2024Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer
Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …
Roche’s Alecensa approved by FDA as lung cancer treatment
April 19, 2024Medical Communications FDA, Oncology, Roche, lung cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
April 10, 2024Research and Development FDA, Oncology, Oryzon, lung cancer
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
